Meeting
2020 ASCO Quality Care Symposium
Biomarker testing patterns and use of targeted therapy in Medicare Fee-for-Service (FFS) beneficiaries newly diagnosed with metastatic non-small cell lung cancer (mNSCLC).
Authors
Anik Patel
Amgen, Global Health Economics, Thousand Oaks, CA
Anik Patel, Aurelien Jamotte, Tara Matsuda, Partha Manas Das, Ehab Elkhouly, Ann Xi, Barton Jones, Anne Murunga, Allison Petrilla, Nathan Markward, Kendall Lee Stevinson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
On-Demand Poster Session: Technology and Innovation in Quality of Care
Track
Technology and Innovation in Quality of Care
Sub Track
Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 29; abstr 278)
DOI
10.1200/JCO.2020.38.29_suppl.278
Abstract #
278
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2018 ASCO Annual Meeting
Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.
First Author: Nathan A. Pennell
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang